A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis

Moderate to Severe Psoriasis Clinical Trial

Official title:
Phase 2/3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis

Status Completed

Clinical Trial Summary

The purpose of this study is to demonstrate the efficacy and safety of Certolizumab Pegol (CZP) in the treatment of moderate to severe chronic plaque Psoriasis (PSO) in Japanese subjects.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Generalized Pustular Psoriasis and Erythrodermic Psoriasis
Moderate to Severe Psoriasis
Psoriasis

Clinical Trial Details

NCT number	NCT03051217
Study type	Interventional
Source	UCB Pharma
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	February 21, 2017
Completion date	January 16, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00678470` - Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis	N/A
Terminated	`NCT01156532` - Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy	N/A
Completed	`NCT00256139` - CLEAR Study: Clinical Experience Acquired With Raptiva Study	Phase 3
Completed	`NCT00936065` - Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis	Phase 4
Completed	`NCT00442650` - Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis	Phase 3
Completed	`NCT05344248` - Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing	Phase 1/Phase 2